Lineage Cell Therapeutics (LCTX) investor relations material

Company overview and business model

• Clinical-stage biotechnology firm focused on cell replacement therapies for serious medical conditions, leveraging a proprietary AlloSCOPE platform for scalable, off-the-shelf pluripotent cell engineering.

• Pipeline includes OpRegen (allogeneic RPE cell therapy in Phase 2a for geographic atrophy in dry-AMD), OPC1 (oligodendrocyte progenitor cell therapy for spinal cord injury), and preclinical programs such as ReSonance for auditory neuropathy.

• Business strategy involves advancing some assets internally and partnering others to maximize value and success probability.

• Programs are supported by collaborations with major pharmaceutical companies and grants from government agencies.

Financial performance and metrics

• Qualifies as a smaller reporting company, allowing for scaled disclosure and reduced reporting requirements under SEC rules.

• Financial statements for the years ended December 31, 2025 and 2024 have been audited by Baker Tilly US, LLP.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, general corporate purposes, R&D expenses, and capital expenditures.

• May allocate a portion of proceeds to acquisitions or investments in businesses or product candidates, though no current commitments exist.

• Pending use, proceeds will be invested in short-term, interest-bearing, investment-grade securities or government securities.